$MRK, $PFE Reveal findings from late-stage trial evaluating STEGLATRO in patients with Type 2 Diabetes and Atherosclerotic Cardiovascular Disease    #Merck    #Pfizer    #Type2Diabetes    #Diabetes      #Cardiovascular   #CV     https://t.co/8b7i4NVvvC